Circulating tumor cells (CTCs) transit through the bloodstream and they exhibit heterogeneity in their expression of epithelial and mesenchymal marker proteins, including the cadherin proteins. Based on these findings, researchers from Massachusetts General Hospital and Harvard Medical School evaluated the potential of the dual anti-cadherin antibody, 23C6, in targeting CTC-dependent blood-borne metastasis.
Trisalus Life Sciences Inc. agreed to merge with Medtech Acquisition Corp. (MTAC) in a deal that allows the drug/device company’s management to meet three out of three goals: quick cash, retained control and faster completion of key clinical trials.
Transcode Therapeutics Inc. has reported positive preclinical results with its lead candidate, TTX-MC138, which targets microRNA-10b (miR-10b). The company evaluated the bioactivity of TTX-MC138 monotherapy in a murine model of pancreatic adenocarcinoma.
